Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5UJ9P)

Drug Name

IMU-838 Drug Info

Synonyms

Vidofludimus; 717824-30-1; 4SC-101; SC12267; UNII-8Y1PJ3VG81; SC 12267; CHEMBL197194; 8Y1PJ3VG81; Vidofludimus(4SC-101; SC12267); Vidofludimus [INN]; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; IMU-838; DTXSID50431325; HMS3740I15; AOB87354; BCP14555; ZINC14960644; s7262; AK; Vidofludimus

Indication

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2/3	[1]

Therapeutic Class

Antiviral Agents

Cross-matching ID

PubChem CID: 9820008
CAS Number: CAS 717824-30-1
TTD Drug ID: DM5UJ9P

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting HUMAN dihydroorotate dehydrogenase (DHODH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[3]
FA-613	DMTHLB8	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HUMAN dihydroorotate dehydrogenase (DHODH)	TT3UY29	PYRD_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04379271) A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19). U.S. National Institutes of Health.
2	IMU-838 Targeting DHODH
3	On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem. 2013 Apr 25;56(8):3148-67. doi: 10.1021/jm301848w.
4	Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral response. J Gen Virol. 2017 May;98(5):946-954.